Ganirelix Research: What 318 Studies Show (2026) | RetatrutideCompare

Ganirelix — 318 studies indexed on PubMed. Competitive GnRH receptor antagonist used in IVF. Half-life: ~13 hours. FDA status: FDA-approved (1999).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Ganirelix?

There are approximately 318 studies indexed on PubMed that mention Ganirelix (Antagon, Orgalutran), based on a search last updated 2026-06-18.

Is Ganirelix FDA-approved?

FDA status: FDA-approved (1999).

How does Ganirelix work?

Competitive GnRH receptor antagonist used in IVF.

Reference facts

Also known as: Antagon, Orgalutran
Category: GnRH & Reproductive
Mechanism of action: Competitive GnRH receptor antagonist used in IVF.
Targets: GnRH receptor (antagonist)
Indications under research or approved: IVF — prevention of premature LH surge
Regulatory status (reference entry): FDA-approved (1999)
Half-life: ~13 hours
Sequence notes: Decapeptide GnRH antagonist with multiple D-amino acid substitutions.
Molecular weight (Da): 1570
Originator / sponsor: Organon / Merck
First reported: 1992

Primary References

Ganirelix FDA label

Explore research articles about Ganirelix

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.